Jeil PharmaceuticalLtd Past Earnings Performance
Past criteria checks 2/6
Jeil PharmaceuticalLtd has been growing earnings at an average annual rate of 14.2%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 1.9% per year. Jeil PharmaceuticalLtd's return on equity is 3%, and it has net margins of 0.7%.
Key information
14.2%
Earnings growth rate
14.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 1.9% |
| Return on equity | 3.0% |
| Net Margin | 0.7% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How Jeil PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 726,394 | 5,005 | 129,129 | 45,727 |
| 30 Sep 23 | 718,168 | 3,638 | 128,045 | 42,828 |
| 30 Jun 23 | 717,079 | 3,944 | 127,832 | 40,866 |
| 31 Mar 23 | 733,281 | 3,533 | 128,061 | 39,991 |
| 31 Dec 22 | 722,230 | -13,091 | 128,527 | 41,147 |
| 30 Sep 22 | 723,809 | -20,556 | 131,103 | 40,957 |
| 30 Jun 22 | 729,397 | -17,107 | 128,010 | 44,838 |
| 31 Mar 22 | 710,234 | -15,079 | 128,826 | 41,084 |
| 31 Dec 21 | 700,693 | -12,473 | 126,989 | 38,974 |
| 30 Sep 21 | 700,569 | -1,128 | 124,225 | 36,720 |
| 30 Jun 21 | 692,115 | -343 | 125,625 | 31,218 |
| 31 Mar 21 | 690,946 | 1,781 | 121,776 | 28,401 |
| 31 Dec 20 | 691,325 | 6,916 | 119,493 | 24,270 |
| 30 Sep 20 | 685,674 | -6,977 | 117,848 | 24,844 |
| 30 Jun 20 | 679,369 | -6,303 | 120,419 | 22,613 |
| 31 Dec 19 | 671,407 | -10,239 | 121,210 | 22,114 |
Quality Earnings: A271980 has a large one-off gain of ₩614.5M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: A271980 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A271980 has become profitable over the past 5 years, growing earnings by 14.2% per year.
Accelerating Growth: A271980 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: A271980 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (36.1%).
Return on Equity
High ROE: A271980's Return on Equity (3%) is considered low.